Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
This coincides with our findings demonstrating that GLP-1RA does reduce the risk of pneumonia and has undeniable positive and safe effects in patients with novel coronavirus pneumonia
A total of 19.7% of the participants in the tirzepatide group had a reduction in body weight of at least 30% (an exploratory end point) as compared with 6.9% of those in the semaglutide group, which indicated that the likelihood of meeting this weight-reduction target with tirzepatide was 2.8 times as high as that with semaglutide
The primary composite outcome occurred in 6.5 percent of the semaglutide group compared to 8.0 percent in the placebo group over the trial period
A missed dose is skipped instead of doubled
US$ 29.13
US$ 24.20
US$ 20.27
US$ 24.25
